Concepedia

Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients

Rafael Reis, Laurence Labat, Marie Allard, Pascaline Boudou‐Rouquette, Jeanne Chapron, Audrey Bellesœur, Audrey Thomas‐Schoemann, Jennifer Arrondeau, Frédérique Giraud, Jérôme Alexandre,

Journal of Pharmaceutical and Biomedical Analysis · 2018 · 64 citations · 18 references

DOI

Concepts

References

18

Cancer statistics, 2016

Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2016 · 16.2K citations · Full text

, , +16

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa et al. · New England Journal of Medicine · 2013 · 3.4K citations · Full text

, , +15

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

Martin Reck, R. Kaiser, Anders Mellemgaard et al. · The Lancet Oncology · 2014 · 948 citations · Full text

, , +11

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials

James Chih‐Hsin Yang, Lecia V. Sequist, Caicun Zhou et al. · Annals of Oncology · 2016 · 188 citations

, , +17

A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer

Martin Reck, R. Kaiser, C. Eschbach et al. · Annals of Oncology · 2011 · 149 citations · Full text

, , +9